Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients

Eur Urol. 1990;17(3):229-35. doi: 10.1159/000464045.

Abstract

In 17 prostatic cancer patients, changes in the plasma lipoprotein pattern, including high density lipoprotein (HDL) subfractions, and in glucose tolerance were compared after 6 months on parenteral polyestradiol phosphate (PEP; Estradurin, 80 or 160 mg/month) with the respective changes in orchiectomized patients. In the estrogen group there was no change in the total serum cholesterol level, whereas in the orchiectomy group an increase of 10% was observed. Estrogen therapy resulted in a significant increase of serum HDL (11%) and HDL2 cholesterol (26%) levels; in the orchiectomy group these fractions remained unchanged. Estrogen therapy induced a significant decrease in total serum triglycerides (24%) and in low density lipoprotein triglycerides (27%); in the orchiectomy group reverse changes were observed. PEP treatment caused changes in the serum lipoprotein pattern, which apparently decreases the risk of atherosclerosis.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Blood Glucose / metabolism*
  • Cholesterol / blood*
  • Estradiol / analogs & derivatives*
  • Estradiol / blood
  • Estradiol / therapeutic use
  • Estradiol Congeners / therapeutic use*
  • Glucose Tolerance Test
  • Humans
  • Lipoproteins / blood*
  • Male
  • Middle Aged
  • Orchiectomy*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / therapy*
  • Testosterone / blood

Substances

  • Blood Glucose
  • Estradiol Congeners
  • Lipoproteins
  • Testosterone
  • Estradiol
  • Cholesterol
  • polyestradiol phosphate